Daniel Rubin is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3401 N Broad St
Philadelphia, PA 191405103
Telephone
215-707-4600Registry record last updated 13 Apr 2018.
Clinical trials
- At-home Walking Cadence Functional Assessment and Recovery Trajectory for Older Adults Undergoing Major Surgery
Sponsor: University of Chicago
- Readmission Prevention Pilot Trial in Diabetes Patients
Sponsor: Temple University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
45.1%GLP-1 receptor agonist23.9%Mounjaro44%Trulicity35%Ozempic21%Part D<11 patientsInsulin Analog7.7%Lantus Solostar100%Part D≥18 patients+ 2 more classes in this area
Hormonal (systemic)
32.5%l-Thyroxine25%Levothyroxine Sodium53%Synthroid47%Part D≥22 patientsThyroid Hormone Synthesis Inhibitor5.1%Methimazole100%Part D<11 patients+ 1 more class in this area
Cardiovascular
15.4%Statin8.8%Atorvastatin Calcium61%Rosuvastatin Calcium39%Part D<11 patientsACE inhibitor6.6%Lisinopril100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2015–2024 per NIH RePORTER. The latest:
- Developing and validating EHR-integrated readmission risk prediction models for hospitalized patients with diabetes
Temple Univ of the Commonwealth
FY2024$514,370R01DK122073 - Developing and validating EHR-integrated readmission risk prediction models for hospitalized patients with diabetes
Temple Univ of the Commonwealth
FY2023$548,401R01DK122073 - Developing and validating EHR-integrated readmission risk prediction models for hospitalized patients with diabetes
Temple Univ of the Commonwealth
FY2022$565,450R01DK122073
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”